Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method.

IF 1.6 4区医学 Q4 IMMUNOLOGY

Acta microbiologica et immunologica Hungarica Pub Date : 2025-09-16 Print Date: 2025-10-09 DOI:10.1556/030.2025.02686

Serpil Genç, Ayten Nur Uzun, Hilal Tanriverdi

{"title":"Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method.","authors":"Serpil Genç, Ayten Nur Uzun, Hilal Tanriverdi","doi":"10.1556/030.2025.02686","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study is to detect the carbapenemase type and to determine the in vitro effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations against Carbapenem-Resistant Klebsiella pneumoniae (CRKP) isolates. A total of 35 CRKP isolates were included to the study. The minimum inhibitory concentrations of ceftazidime/avibactam, meropenem, colistin and tigecycline were determined by broth dilution method. Synergistic effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline were investigated by microdilution checkerboard method. Carbapenemase genes (blaOXA-48, blaNDM, blaKPC, blaIMP, blaVIM) were detected by multiplex PCR. All of the isolates were resistant to meropenem, whereas 77.1% of the isolates were resistant to ceftazidime/avibactam and 14.3% of the isolates were resistant to colistin.The carbapenemase genes of the CRKP isolates were determined as 17 OXA-48+NDM, 9 KPC, 6 OXA-48, 1 NDM, 1 KPC+NDM and 1 KPC+OXA-48. Ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations were synergistic against 5.7% (2/35), 17.1% (6/35), and 5.7% (2/35) of the isolates, respectively. Ceftazidime/avibactam-meropenem was the most effective synergistic combination in our study, showing synergism in 17.1% of isolates, however, the synergistic effect varied depending on the CRKP isolate tested.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"220-225"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta microbiologica et immunologica Hungarica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1556/030.2025.02686","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/9 0:00:00","PubModel":"Print","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this study is to detect the carbapenemase type and to determine the in vitro effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations against Carbapenem-Resistant Klebsiella pneumoniae (CRKP) isolates. A total of 35 CRKP isolates were included to the study. The minimum inhibitory concentrations of ceftazidime/avibactam, meropenem, colistin and tigecycline were determined by broth dilution method. Synergistic effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline were investigated by microdilution checkerboard method. Carbapenemase genes (blaOXA-48, blaNDM, blaKPC, blaIMP, blaVIM) were detected by multiplex PCR. All of the isolates were resistant to meropenem, whereas 77.1% of the isolates were resistant to ceftazidime/avibactam and 14.3% of the isolates were resistant to colistin.The carbapenemase genes of the CRKP isolates were determined as 17 OXA-48+NDM, 9 KPC, 6 OXA-48, 1 NDM, 1 KPC+NDM and 1 KPC+OXA-48. Ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations were synergistic against 5.7% (2/35), 17.1% (6/35), and 5.7% (2/35) of the isolates, respectively. Ceftazidime/avibactam-meropenem was the most effective synergistic combination in our study, showing synergism in 17.1% of isolates, however, the synergistic effect varied depending on the CRKP isolate tested.

查看原文本刊更多论文

棋盘法评价头孢他啶-阿维巴坦联合用药对耐碳青霉烯肺炎克雷伯菌的活性。

本研究的目的是检测碳青霉烯酶类型，并确定头孢他啶/阿维巴坦-粘菌素、头孢他啶/阿维巴坦-美罗培南和头孢他啶/阿维巴坦-替加环素联合用药对耐碳青霉烯肺炎克雷伯菌（CRKP）分离株的体外作用。共纳入35株CRKP分离株。采用肉汤稀释法测定头孢他啶/阿维巴坦、美罗培南、粘菌素和替加环素的最低抑菌浓度。采用微量稀释棋盘法考察头孢他啶/阿维巴坦-粘菌素、头孢他啶/阿维巴坦-美罗培南、头孢他啶/阿维巴坦-替加环素的协同效应。多重PCR检测碳青霉烯酶基因blaOXA-48、blaNDM、blaKPC、blaIMP、blaVIM。所有菌株对美罗培南均耐药，77.1%的菌株对头孢他啶/阿维巴坦耐药，14.3%的菌株对粘菌素耐药。分离株碳青霉烯酶基因分别为17个OXA-48+NDM、9个KPC、6个OXA-48、1个NDM、1个KPC+NDM和1个KPC+OXA-48。头孢他啶/阿维巴坦-粘菌素、头孢他啶/阿维巴坦-美罗培南和头孢他啶/阿维巴坦-替加环素分别对5.7%（2/35）、17.1%（6/35）和5.7%（2/35）的分离菌具有协同作用。头孢他啶/阿维巴坦-美罗培南是本研究中最有效的协同组合，在17.1%的分离株中表现出协同作用，然而，协同效果因所检测的CRKP分离株而异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta microbiologica et immunologica Hungarica IMMUNOLOGY-MICROBIOLOGY

CiteScore

2.30

自引率

13.30%

发文量

审稿时长

>12 weeks

期刊介绍： AMIH is devoted to the publication of research in all fields of medical microbiology (bacteriology, virology, parasitology, mycology); immunology of infectious diseases and study of the microbiome related to human diseases.